Purpose: This study aimed to evaluate the efficacy and safety of montelukast (Mon) + fluticasone propionate (Flu) versus Flu in the treatment of cough variant asthma (CVA) in children.
Methods: Eligible documents were selected from various databases. Weighted mean difference (WMD) and 95% confidence interval (CI) were used to evaluate continuous variables, and categorical variables were evaluated using risk ratio (RR) and 95% CI. Heterogeneity analysis was performed using Cochran's Q test and I statistics, followed by sensitivity analysis and publication bias evaluation.
Results: Nine studies were included, and Flu + Mon was found to significantly improve the total effective rate and reduce cough recurrence compared to Flu. The cough remission and disappearance times in the Mon + Flu group were significantly lower than those in the Flu group. FEV1% recovery in the Mon + Flu group was significantly better than that in the Flu group.
Conclusion: Mon + Flu is effective and safe for the treatment of CVA in children.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696880 | PMC |
| http://dx.doi.org/10.1186/s12890-023-02721-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients.
Rev Alerg Mex
December 2024
Master's in economics, HS Pharmacoeconomic Research, Mexico City, Mexico.
Article Synopsis
- The study aimed to analyze the cost-effectiveness of budesonide/formoterol compared to other asthma treatments at Mexico's National Institute for Respiratory Diseases.
- Budesonide/formoterol had a lower average cost per patient ($733.36 USD) compared to fluticasone/vilanterol ($767.24 USD), and it showed a significant reduction in exacerbations with an incremental cost-effectiveness ratio (ICER) of $613.31 USD for better management.
- Overall, budesonide/formoterol was found to be a very cost-effective treatment option, suggesting it could reduce healthcare costs associated with emergency visits and hospitalizations despite fewer exacerbations per patient.
Effects of flow lamination on aerosolized drug delivery through spatial barriers.
Int J Pharm
December 2024
SkinAxis LLC, Cedar Knolls, NJ, USA. Electronic address:
In this study we evaluated the effects of flow lamination on aerosol flow dynamics and deposition at the exit point in testing models with spatial barriers (narrowing or curving).We compared ModiFlow (MF) to an idealized Standard Spacer (SS) in their efficiency of delivery of aerosolized medication (fluticasone) across different types of spatial barriers. Fluticasone propionate HFA Inhaler from Prasco Labs 220 µg per actuation was used to deliver 1 spray in each test tube.
View Article and Find Full Text PDFComparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.
Adv Ther
December 2024
GSK, US Value Evidence and Outcomes, Collegeville, PA, 19426-0989, USA.
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD among patients experiencing exacerbations despite dual-therapy use. This real-world comparative effectiveness study compared the impact of SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), on COPD exacerbations and mortality.
View Article and Find Full Text PDFMedicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Adv Ther
December 2024
US Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Introduction: The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β-agonist (ICS/LABA).
View Article and Find Full Text PDFParticularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients.
Respir Med
January 2025
Pulmonology Center of the Reformed Church, Munkácsy M. U.70, 2045, Törökbálint, Hungary.
The aim of this study was to analyse the effect of breathing parameters, age, gender and disease status on the lung doses of the two ICS + LABA fixed combination dry powder drugs. Breathing parameters of 113 COPD patients were measured while inhaling through emptied NEXThaler® and Ellipta® inhalers and the corresponding lung doses were calculated. Lung dose of Foster® NEXThaler® was superior to the lung dose of Relvar® Ellipta® in around 85 % of the patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!